Adaptimmune Q1 net loss $48.5M; afami-cel PDUFA Aug 4; secures $125M debt

Adaptimmune Therapeutics PLC

2024-Q1 EPS reported -$0.03 revenue$5,678,000

Revenue $5.7M (down from $47.6M YoY); net loss $48.5M vs profit $1.0M in Q1 2023.
FDA PDUFA date for afami-cel BLA set for August 4, 2024; GMP and GCP inspections ongoing.
Secured up to $125M debt financing with Hercules Capital; first $25M available at close.
Lete-cel pivotal trial IGNYTE-ESO met primary efficacy endpoint; full analysis expected late 2024.
Cash and cash equivalents $140.7M; cash runway extended into late 2025 with anticipated afami-cel revenues.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Adaptimmune Therapeutics PLC reported first quarter ended March 31, 2024 results: revenue $5.7 million.

Period: first quarter ended March 31, 2024
Revenue: $5.7 million
Result: reported results

Exact text from the filing

Revenue for the three months ended March 31, 2024, was $5.7 million

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001558370-24-008210

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.